Pelthos Therapeutics PTHS
NYSE PTHS
$20.45 +0.19 (+0.94%)
As of: Oct 20, 2026 · 3:52 PM EDT

Pelthos Therapeutics (PTHS) EBITDA Margin (2026)

Updated

Pelthos Therapeutics' EBITDA Margin came in at -102.56% for Q2 2026, up 3.70 percentage points from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) EBITDA Margin (2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Pelthos Therapeutics reported EBITDA Margin of -121.63%; for FY2025, it was -179.49%.

  • Business Quant data shows PTHS's EBITDA Margin at -106.25% (Q1 2026), -111.52% (Q4 2025) and -197.26% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 35.95%
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 49.01%
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn -
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 33.11%
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 46.01%
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn -124.26%
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 39.16%
10 Pelthos Therapeutics 72.38 Mn -16.01 Mn 11.99 Mn -101.04%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -101.04%
Mar 31, 2026 -104.47%
API Access

Pelthos Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=PTHS&period=max&api_key=YOUR_API_KEY